The impact of current and novel anti-diabetic therapies on cardiovascular risk.
about
Dapagliflozin in patients with type 2 diabetes mellitus.Effects of glucagon-like peptide-1 receptor agonists on renal functionCardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus.Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Deciphering ventricular GLP-1 action: time for a change of heart.
P2860
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
@en
type
label
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
@en
prefLabel
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
@en
P2093
P2860
P356
P1433
P1476
The impact of current and novel anti-diabetic therapies on cardiovascular risk.
@en
P2093
Gopinath Sutendra
Jagdip S Jaswal
John R Ussher
P2860
P304
P356
10.2217/FCA.12.68
P577
2012-11-01T00:00:00Z